{"schema_version":"secwatch.filing_event.v1","accession":"0001601830-24-000009","form_type":"8-K","ticker":"RXRX","cik":"0001601830","company_name":"RECURSION PHARMACEUTICALS, INC.","filed_at":"2024-01-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.771288+00:00","generated_at":"2026-06-06T13:33:14.825745+00:00","sec_items":["5.03","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"high","headline":"Recursion Pharmaceuticals amends bylaws to enhance proxy disclosure and conform to Delaware law","bullets":["Bylaw amendments enhance procedural mechanics and disclosure for stockholder director nominations and proposals (except Rule 14a-8).","Amendments incorporate universal proxy rules per Rule 14a-19 and conform to recent DGCL changes.","Updated provisions regarding Board committees, officers, written consent, indemnification, and exclusive forum.","Compensation recovery policy reflected in limitation on indemnification.","Effective January 25, 2024; filed as Exhibit 3.1."],"urls":{"canonical":"https://secwatch.observer/filing/0001601830-24-000009","json":"https://secwatch.observer/filing/0001601830-24-000009.json","markdown":"https://secwatch.observer/filing/0001601830-24-000009.md","text":"https://secwatch.observer/filing/0001601830-24-000009.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1601830/000160183024000009/0001601830-24-000009-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1601830/000160183024000009/rxrx-20240125.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T13:33:14.825745+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cd112ccf4baf7bd65133a5834997da0d137efd00","claim":"RECURSION PHARMACEUTICALS, INC.: Amended and restated Bylaws to enhance stockholder proposal procedures, adopt universal proxy rules, conform to DGCL, update director/officer provisions, and make other revisions (effective 2024-01-25).","evidence_excerpt":"On January 25, 2024, the Board of Directors (the “Board”) of Recursion Pharmaceuticals, Inc. (the “Company”) amended and restated the Company’s Bylaws (the “Bylaws”), effective immediately.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1601830/000160183024000009/0001601830-24-000009-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2024-01-25"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}